OncoStatyx has a preclinical program developing a small molecule epigenetic medicine which is safe, inexpensive, orally available & useful against a broad range of carcinomas (solid tumor) cancers to:
• TREAT. Patients diagnosed with carcinoma type cancers such as breast, prostate,
colorectal, non small lung cell cancer and possibly gastric, bladder, liver, pancreas
to improve the effectiveness of other therapies (radiation, chemo, other oncology
drugs)
• CURE. Achieve a functional 'cure' by either complete remission (disease-free
survival) and / or greatly extend progression-free survival from months/years to
years/decades through the direct effects of HEXIM1 induction
• PREVENT. Prophylactic medicine to regularly induce HEXIM1 in aging populations
in the US and Globally to dramatically shrink the emotional and economic burden of carcinoma cancers
• MECHANISM of ACTION. We are developing unique composition of matter / new chemical entity small molecule therapeutic which functi...
OncoStatyx has a preclinical program developing a small molecule epigenetic medicine which is safe, inexpensive, orally available & useful against a broad range of carcinomas (solid tumor) cancers to:
• TREAT. Patients diagnosed with carcinoma type cancers such as breast, prostate,
colorectal, non small lung cell cancer and possibly gastric, bladder, liver, pancreas
to improve the effectiveness of other therapies (radiation, chemo, other oncology
drugs)
• CURE. Achieve a functional 'cure' by either complete remission (disease-free
survival) and / or greatly extend progression-free survival from months/years to
years/decades through the direct effects of HEXIM1 induction
• PREVENT. Prophylactic medicine to regularly induce HEXIM1 in aging populations
in the US and Globally to dramatically shrink the emotional and economic burden of carcinoma cancers
• MECHANISM of ACTION. We are developing unique composition of matter / new chemical entity small molecule therapeutic which functions as an inhibitor of epigenetic modulator of gene expression KDM5B which demethylates histones in the promoter regions of certain genes and thus silences them. The most important target of KDM5B silencing is the tumor suppressor protein HEXIM1, and by inhibiting KDM5B we turn tumor suppressor HEXIM1 back on and turn off cancer properties of the cells in solid tumors.
• KDM5B INHIBITORS. Many other groups have tried drugging KDM5B using neoclassical high throughput screening methods. This approach failed however due to difficulties encountered in cells when competing with a very abundant cofactor. We targeted a different region of the KDM5B catalytic domain however, then used structure based design and 3D molecular modelling to identify potential hits and have druglike lead compounds in hand that are shrinking tumors in mouse models of breast cancer at 5 nanomolar and below. These leads now need to be improved pharmacologically to generate clinical candidates for clinical trials.
More information

Employees

Matt Lawes
Admin
Matt Lawes CEO Entrepreneurial PhD MBA with operational experience in sales & marketing leadership for Life Science industry at large and small companies